CALGARY, Alberta., April 8, 2021 — Syantra Inc., a precision healthcare company that’s changing the way cancer is detected, starting with breast cancer, today announced the appointment of Dr. Randy Moore as the company’s Medical Director. Dr. Moore is one of the founders of Syantra and has served on Syantra’s Board of Directors. In his new role, Dr. Moore will oversee the operation and administration of Syantra’s laboratory to assure that quality patient services are provided.
“We’re delighted to have Randy on board in this capacity as Medical Director. He is an accomplished surgeon and a passionate advocate for translating sound research principles into innovations that enhance patient care,” said Bob Shepherd, President and Chief Executive Officer at Syantra. “He will be invaluable as we move into the commercialization of the Syantra.”
“I can hardly think of a better way to positively impact the lives of patients than by working with Syantra in this capacity,” said Dr. Moore. “When I operate on a patient, I can save one patient’s life. In my career, I’ve operated on over 3000 patients for aneurysm disease. But by changing the way breast cancer patients are managed worldwide, we can save millions of lives.”
Dr. Moore is a Fellow of the Royal College of Surgeons of Canada with a Certificate of Special Competency in Vascular Surgery, a Fellow of the American College of Surgeons and a member of the Canadian Society for Vascular Surgery, where he has previously served as the Research Chair, as well as the Society for Vascular Surgery. He has previously served two terms as President of Vascular Surgery for the Alberta Medical Association, as well as Division Chief of Vascular Surgery for the Calgary Health Region and has a cross appointment with the Schulich School of Engineering at the University of Calgary, with multiple published research studies related to complex Aortic Aneurysm Repair, Vascular Hemodynamics and Vascular Imaging.
In addition to being a co-founder of Syantra (KRS Biopharma) Dr. Moore is also the co-founder and director of Montreal-based ViTAA (Virtual Touch Aortic Aneurysm), a medical solutions company whose software maps and identifies regions of aortic strength and weakness prior to intervention.
